The US Food and Drug Administration (FDA) has granted approval for Foundation Medicine’s FoundationOne Liquid CDx as a companion diagnostic for Takeda’s Exkivity (mobocertinib).
Exkivity already secured approval from the FDA for locally advanced or metastatic non-small cell lung cancer adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
FoundationOne Liquid CDx is claimed to be the only blood-based comprehensive genomic profiling test that received the US regulator’s approval for detecting EGFR exon 20 insertion mutations to identify suitable patients to treat with Exkivity.
This qualitative next-generation sequencing-based in vitro diagnostic test has the ability to analyse over 300 cancer-related genes for genomic alteration from a simple blood sample.
It specifically analyses 324 genes by deploying circulating cell-free DNA.
The prescription use-only test received FDA approval to report short variants in 311 genes, as well as a companion diagnostic to detect patients who are expected to benefit from treatment with specific therapies.
Foundation Medicine chief medical officer Mia Levy said: “Cancer is an incredibly complex disease, so it’s critical that oncologists leverage companion diagnostics, which are high-quality, well-validated genomic tests to inform treatment decisions for their patients.
“We’re proud of the work we’ve done with Takeda to develop blood and tissue-based companion diagnostics for therapies in their precision oncology pipeline, including this recent approval for Exkivity.”
